<DOC>
	<DOCNO>NCT02137889</DOCNO>
	<brief_summary>This study ass safety preliminary efficacy escalate dos VAY736 relapse refractory CLL patient .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics , Pharmacodynamics VAY736 Relapsed Refractory CLL Patients</brief_title>
	<detailed_description>This Phase 1 , multicenter , open-label , study investigate safety , pharmacokinetics , pharmacodynamics , preliminary antil-CLL activity VAY736 patient relapsed/refractory CLL receive least two prior regimen . The study include one arm dose escalation phase two arm dose expansion phase .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>Dose escalation : Relapsed/refractory CLL follow least two prior treatment regimen Dose expansion : Arm 1 : Relapsed/refractory CLL follow two three prior treatment regimen Arm 2 : Relapsed/refractory CLL follow four prior treatment regimen Discontinued previous anticancer investigational therapy include radiation , radioimmunotherapy , monoclonal antibody therapy least 28 day 5 halflives investigational product , whichever longer , study treatment administration , must recover fully adverse effect treatment begin study treatment Discontinued prior alemtuzumab therapy least 6 month Age 18 year Eastern cooperative oncology group ( ECOG ) performance status grade ≤ 1 Life expectancy &gt; 3 month Meet follow laboratory criterion ( must obtain within 14 day enrollment ) : • Adequate endorgan function assess laboratory test , specify protocol . Written inform consent obtain prior screen procedure Major surgery within 28 day study treatment recover fully adverse effect major minor surgical procedure study treatment History another primary malignancy currently clinically significant currently require active intervention ( except adequately treat situ carcinoma cervix nonmelanoma carcinoma skin curatively treat malignancy treat prior 3 month expect require treatment recurrence course study ) . Prior anaphylactic severe infusion reaction patient unable tolerate human immunoglobulin monoclonal antibody administration Clinically significant central nervous system disease Myocardial infarction within 6 month prior enrollment New York Hospital Association ( NYHA ) Class III IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia significant conduction system abnormalities opinion investigator History active infection require systemic therapy within 14 day study treatment . Prophylactic antibiotic antiviral therapy permit . Active autoimmune disease require immunosuppressive therapy Known history human immunodeficiency virus ( HIV ) active infection hepatitis C virus hepatitis B virus active bacterial , viral , fungal infection require systemic therapy Ongoing corticosteroid use ( &gt; 10 mg/day prednisone equivalent ) Pregnant nursing ( lactate ) woman . Sexually active male must use condom intercourse take drug 3 month stop treatment father child period . A condom require use also vasectomize men order prevent delivery drug via seminal fluid .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>CLL</keyword>
</DOC>